Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Manufacturers Notice of Application - 2017 > Sigma Aldrich Research Biochemicals, Inc.

Manufacturers Notice of Application - 2017

[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Pages 19085-19086]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08344]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc.

ACTION: Notice of application.


DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled Substance Drug Code Schedule
Cathinone 1235 I
Methcathinone 1237 I
Mephedrone (4-Methyl-N-methylcathinone) 1248 I
Aminorex 1585 I
Alpha-ethyltryptamine 7249 I
Lysergic acid diethylamide 7315 I
Tetrahydrocannabinols 7370 I
4-Bromo-2,5-dimethoxyamphetamine 7391 I
4-Bromo-2,5-dimethoxyphenethylamine 7392 I
4-Methyl-2,5-dimethoxyamphetamine 7395 I
2,5-Dimethoxyamphetamine 7396 I
3,4-Methylenedioxyamphetamine 7400 I
N-Hydroxy-3,4-methylenedioxyamphetamine 7402 I
3,4-Methylenedioxy-N-ethylamphetamine 7404 I
3,4-Methylenedioxymethamphetamine 7405 I
Dimethyltryptamine 7435 I
Psilocybin 7437 I
5-Methoxy-N,N-diisopropyltryptamine 7439 I
1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I
N-Benzylpiperazine 7493 I
MDPV (3,4-Methylenedioxypyrovalerone) 7535 I
Methylone (3,4-Methylenedioxy-N-methylcathinone) 7540 I
Heroin 9200 I
Normorphine 9313 I
Norlevorphanol 9634 I
Amphetamine 1100 II
Methamphetamine 1105 II
Nabilone 7379 II
1-Phenylcyclohexylamine 7460 II
Phencyclidine 7471 II
Cocaine 9041 II
Codeine 9050 II
Ecgonine 9180 II
Levomethorphan 9210 II
Levorphanol 9220 II
Meperidine 9230 II
Metazocine 9240 II
Methadone 9250 II
Morphine 9300 II
Thebaine 9333 II
Levo-alphacetylmethadol 9648 II
Remifentanil 9739 II
Sufentanil 9740 II
Carfentanil 9743 II
Fentanyl 9801 II

[[Page 19086]]

The company plans to manufacture reference standards.

Dated: April 18, 2017.

Louis J. Milione,
Assistant Administrator.

[FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility